KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Share-based Compensation: 2009-2024

Historic Share-based Compensation for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Dec 2024 value amounting to $248.0 million.

  • Jazz Pharmaceuticals' Share-based Compensation rose 47.46% to $88.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $290.5 million, marking a year-over-year increase of 25.86%. This contributed to the annual value of $248.0 million for FY2024, which is 9.35% up from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Share-based Compensation of $248.0 million as of FY2024, which was up 9.35% from $226.8 million recorded in FY2023.
  • Jazz Pharmaceuticals' 5-year Share-based Compensation high stood at $248.0 million for FY2024, and its period low was $121.0 million during FY2020.
  • Its 3-year average for Share-based Compensation is $232.3 million, with a median of $226.8 million in 2023.
  • Data for Jazz Pharmaceuticals' Share-based Compensation shows a peak YoY surged of 56.21% (in 2021) over the last 5 years.
  • Over the past 5 years, Jazz Pharmaceuticals' Share-based Compensation (Yearly) stood at $121.0 million in 2020, then soared by 56.21% to $189.0 million in 2021, then climbed by 17.45% to $222.0 million in 2022, then increased by 2.18% to $226.8 million in 2023, then climbed by 9.35% to $248.0 million in 2024.